A Director at Invitae (NYSE: NVTA) is Buying SharesBy Carrie Williams
Following this transaction Eric Aguiar’s holding in the company was increased by 100% to a total of $25.46 million. In addition to Eric Aguiar, 2 other NVTA executives reported Buy trades in the last month.
Based on Invitae’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $6.28 million and GAAP net loss of $24.97 million. In comparison, last year the company earned revenue of $2.19 million and had a GAAP net loss of $22.53 million. The company has a one year high of $11.85 and a one year low of $5.66. Currently, Invitae has an average volume of 1.07M.
The insider sentiment on Invitae has been positive according to 14 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It offer tests for disorders in cardiovascular, hereditary cancer, neurology, pediatrics, and other rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.